Fast Five Quiz: Achondroplasia
Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in every 10,000-30,000 infants, with no differences according to race or sex. Systematic literature reviews have demonstrated a substantial burden on affected individuals and their families, including impacts on various aspects of health-related quality of life, healthcare resource utilization, and associated costs. Management of achondroplasia usually requires a multidisciplinary approach involving geneticists, pediatricians, orthopedic surgeons, and other specialists to address various complications that might arise throughout life.
What do you know about achondroplasia? Check your knowledge with this quick quiz.
Medscape © 2025 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Achondroplasia - Medscape - May 08, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
Medscape at 30: Three Decades of Big Events in Medicine
Medscape turns 30 in 2025. To mark this milestone, the Medscape 2050 project looks at what the field of medicine may look like 25 years from now. But the future is also shaped by the past. Below we look at the previous 30 years through the lens of Medscape News' coverage of the headlines and events that helped define medicine since 1995. May 22, 1995: Medscape Launches Remember what the early days of the internet were like? That's Medscape, launched out of a tiny office in Manhattan on May 22, 1995, by a scrappy group of people who had a great idea for a website to serve a physician readership. Here's what those early days were like. 1996: Highly Active Antiretroviral Therapy (HAART) Revolutionizes HIV/AIDS Treatment John G. Bartlett, MD, offers a thorough breakdown of HAART's evolution, with notable mention of a certain director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), Anthony Fauci. Ten years after this breakthrough, Medscape continued in-depth coverage, including this long Q&A with Richard Elion, MD. March 27, 1998: Viagra Approved by the FDA The first oral treatment for erectile dysfunction became a cultural phenomenon and, from a news perspective, the gift that kept on giving, leading to ongoing coverage not just in the ensuing years but for decades — including evidence 26 years later that the little blue pill may help prevent Alzheimer's. 1999: Vioxx and COX-2 Inhibitors Introduced The arrival of the new class of painkillers was less newsworthy than what followed later, with Vioxx linked to heart risks and pulled from the market. The fallout brought harsh questions about its initial FDA approval. March 2003: SARS Outbreak The global epidemic led to the first modern pandemic response, and just like the pandemic that would follow 17 years later, it spurred ongoing Medscape coverage that may seem quaint in retrospect. May 2005: Medscape Celebrates 10 Years Our 10th anniversary brought a comprehensive reckoning of some of the major medical advances from 1995 to 2004, including analysis of impactful stories across all specialties. November 24-25, 2005: First Successful Face Transplant Performed A new day for reconstructive surgery when surgeons grafted the donor nose, lips, and chin to the face of a 38-year-old French woman whose lips and nose were ripped off in a dog attack. The breakthrough procedure led to a sharp debate about whether the surgery should have happened at all. 2009: H1N1 (Swine Flu) Pandemic Six years after SARS, H1N1 gave us the first official flu pandemic in decades, prompting massive vaccine production, as well as inevitable comparisons to the 1918 pandemic, with the two strains, separated by 91 years, sharing similar features. March 23, 2010: Affordable Care Act (ACA) Signed Into Law in the US President Obama's signature legislation was a seismic health policy shift increasing insurance access. The law has been scrutinized (and challenged) ever since. Meanwhile, more than 24 million people signed up for ACA Marketplace Coverage for 2025, a new record. 2013: Angelina Jolie's BRCA1 Op-ed Spurs Genetic Testing Boom Celebrities can single-handedly transform public discourse on health issues, and Jolie did just that with hereditary cancer risk. As a result of the 'Angelina Jolie Effect,' BRCA testing doubled. 2014: Ebola Outbreak in West Africa While the outbreak highlighted weaknesses in global public health infrastructure, Medscape highlighted what US clinicians needed to know — as well as what they didn't know. In September, the WHO convened a 2-day meeting in Geneva to discuss therapies derived from survivors' blood. October 26, 2019: US Declares Opioid Epidemic a National Health Emergency Addiction treatment, regulation, and pharmaceutical accountability all became part of public medical discourse as part of the outcry to declare a state of emergency on opioids. President Trump eventually declared the crisis a national public health emergency. In 2019, opioid-related deaths reached almost 72,000, a new high. Death rates continued to rise well into 2020. 2019: Measles Outbreaks Reemerge Due to Vaccine Hesitancy A global spike in cases, especially in the US and Europe, foreshadowed measles news in 2025, but physicians were just as concerned then about the measles and vaccine hesitancy. 2020: COVID-19 Global Pandemic Declared Perhaps the biggest medical news event in Medscape's history, and as you can see, this selection of six headlines offers a telling timeline of just what was going on — what we knew and a whole lot we didn't…. March 11, 2020, WHO declares COVID-19 a pandemic So You Have a COVID-19 Patient; How Do You Treat Them? COVID-19: Time to 'Take the Risk of Scaring People' A Decade of Telemedicine Policy Has Advanced in Just 2 Weeks Year of COVID: Everything We Thought We Knew Was Wrong 'Death by 1000 Cuts': Medscape National Physician Burnout & Suicide Report 2021 June 24, 2022: US Overturns Roe v. Wade (Dobbs Decision) One of the most impactful legal decisions in US history with major implications for reproductive healthcare. Aside from the news itself, the decision spurred Medscape coverage on both sides of the issue in the medical world. Ob/Gyns on the Day That Roe v. Wade Was Overturned Pro-Life Ob/Gyns Say Dobbs Not End of Abortion Struggle Roe v. Wade : Medical Groups React to Supreme Court Decision February 2025: Trump Administration Announces Significant Cuts to Medical Research Funding The administration imposed a 15% cap on 'indirect costs' for NIH grants, reducing funds allocated for overhead expenses such as facilities and administrative support. But that was just one aspect of the cuts announced, reversed, or left in place, causing fear and uncertainty in the medical science community. What Happens When Science Stops Exodus of Infectious Disease Experts Imperils Public Safety Exclusive-Trump Health Layoffs Include Staff Overseeing Bird Flu Response, Source Says 2025: Measles Outbreak Response Hindered by Confusion A surge in measles cases across several states drove Medscape coverage, aiding clinicians who may have never seen a case of measles in their career while also detailing just how unprepared physicians and public health officials are for this widening crisis.
Medscape
18 hours ago
- Medscape
ERA 2025
Semaglutide Significantly Improves Chronic Kidney Disease The landmark FLOW study shows the benefits extend to kidney, cardiovascular, and mortality outcomes in high-risk patients with type 2 diabetes and CKD. Medscape Medical News , May 24, 2024 Semaglutide Significantly Improves Chronic Kidney Disease Antinephrin Autoantibodies: Biomarker for Kidney Disease? Using an innovative analysis technique, researchers identified antinephrin autoantibodies as markers of difficult to diagnose kidney diseases. Medscape Medical News , May 26, 2024 Antinephrin Autoantibodies: Biomarker for Kidney Disease? SGLT2 Inhibitors Add to GLP-1s' Cardio, Kidney Benefits The largest analysis to date details added effects of SGLT2 inhibitors among those with type 2 diabetes when combined with GLP-1 receptor agonists. Medscape Medical News, Jun 03, 2024
Business Upturn
a day ago
- Business Upturn
QPS Celebrates 30th Anniversary
Newark, Del., United States: QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as a global leader in contract research. Over the past 30 years, the company has grown from a single office in Delaware, USA to a widely respected, global, full-service CRO with 8 locations spread across the US, EU, Asia, India and Australia, a clinical trial network of over 700 sites and an increased focus on leveraging the power of AI to accelerate clinical trials. This press release features multimedia. View the full release here: Dr. Benjamin Chien founder and CEO of QPS Holdings, LLC. Over the years, QPS has grown from a small molecule bioanalysis shop of three people to a global CRO with more than 1,200 employees. '30 years is a major milestone for QPS and I couldn't be more proud of the hard-working and innovative people who choose to work at QPS. They are the backbone of the company, and I am very grateful for their valuable contributions,' said founder and CEO of QPS, Dr. Benjamin Chien. 'Through QPS, the pharmaceutical and biotechnology industries have access to dedicated, focused scientific expertise across the drug development spectrum. In facilities around the world, QPS has assembled best-in-class instruments, platforms, people and processes required to conduct the studies necessary to support client drug discovery and development programs focused on obesity, type 2 diabetes, oncology, CNS diseases, cell and gene therapy, and more,' said Dr. Chien. Since its humble beginnings, QPS has expanded its service options, to include pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs, cell therapy products, clinical trials, central lab services, and a full range of clinical research services. QPS is known for high-quality data, technical expertise, delivery of promised study timelines, collaborative solutions, and customer-focused strategies. Going forward, QPS plans to continue delivering custom-built research services that accelerate pharmaceutical breakthroughs across the globe. ABOUT QPS HOLDINGS, LLC QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks, PBMCs and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit or email [email protected] . View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
